Tiziana Life Sciences Ltd (TLSA:NASDAQ) closed at $0.950 on October 23, 2026, down 4.99% on the day. The stock trades 54.8% below its 52-week high of $2.10 and 25.0% above its 52-week low of $0.760. Over the past year, it lost 51.0%. Tiziana Life Sciences Ltd is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since October 23, 2025, TLSA closed higher on 95 days (38%). Its best day was September 17, 2026 (+25.97%) and its worst was June 3, 2026 (-13.24%). The stock moved 10% or more in a single session 12 times. It opened at least 5% above the previous day's high 1 time.
Tiziana Life Sciences PLC is involved in the business of developing novel therapeutics for cancer with a focus on late-stage growth and complementary diagnostic tools, with the capability of predicting disease aggressiveness and prognosis in breast cancer patients. The group also has interests, beyond pure oncology, in the discovery and development of monoclonal antibody-based biologics used to benefit patients with inflammatory and auto-immune disorders. The company has a single reporting segment, The Research, and Development of Biotechnological and Pharmaceutical Products. Its lead compound, milciclib (TZLS-201), is a molecule which blocks the action of specific enzymes involved in cell division as well as a number of other protein kinases.
Find more stocks like TLSA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.